Pharmaceutical Technology2 天
Risk adjusted net present value: What is the current valuation of Calidi Biotherapeutics ...
NNV1 is an oncolytic virus commercialized by Calidi Biotherapeutics, with a leading Phase I program in Anaplastic Astrocytoma;Glioblastoma Multiforme (GBM);Oligodendroglioma;High-Grade ...
Florida man battles flesh-eating bacteria
A Florida man is hospitalized and fighting for his life after contracting a rare flesh-eating bacterial infection believed to ...